Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Pharmacol Sci. 2009 Nov;30(11):592-9. doi: 10.1016/j.tips.2009.08.004.

Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.

Author information

1
Centre for Nanotechnology, Biomaterials and Tissue Engineering, University College London, London, UK.

Abstract

Nanoscale drug delivery systems using liposomes and nanoparticles are emerging technologies for the rational delivery of chemotherapeutic drugs in the treatment of cancer. Their use offers improved pharmacokinetic properties, controlled and sustained release of drugs and, more importantly, lower systemic toxicity. The commercial availability of liposomal Doxil and albumin-nanoparticle-based Abraxane has focused attention on this innovative and exciting field. Recent advances in liposome technology offer better treatment of multidrug-resistant cancers and lower cardiotoxicity. Nanoparticles offer increased precision in chemotherapeutic targeting of prostate cancer and new avenues for the treatment of breast cancer. Here we review current knowledge on the two technologies and their potential applications to cancer treatment.

PMID:
19837467
DOI:
10.1016/j.tips.2009.08.004
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center